Using the California Cancer Registry from 2005-2012 a total of 10,031 patients with low grade Ta or T1 bladder cancer were identified. They assessed trends and performed multivariate analyses to determine predictors for use as well as calculated recurrence free-survival.
Only 5.1% patients received immediate intravesical chemotherapy which increased over the time period from 1.7% to 9.6%. The recurrence rate at 2 years was 25% and 30% among those that did and did not receive immediate intravesical chemotherapy.
Further studies in larger nationwide databases are needed to confirm these findings and methods to improve adherence to this guideline recommended treatment are needed. Perhaps with the AUA and EAU NMIBC guidelines delineating risk stratification approach to use of immediate postoperative MMC will improve this adherence.
Presented by: Neil Pugashetti, University of California at Davis
Written By: Stephen B. Williams, M.D., Assistant Professor in Urology, The University of Texas Medical Branch, Galveston, TX. and Ashish M. Kamat, M.D. Professor, Department of Urology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX.
at the 2017 AUA Annual Meeting - May 12 - 16, 2017 – Boston, Massachusetts, USA